On a relative basis, the stock has outperformed the S&P 500 by 0.65% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.08% in the last 1 week, and is up 2.27% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -19.62% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $34.42 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $24.50 and the 200 Day Moving Average price is recorded at $25.29.
The stock has recorded a 20-day Moving Average of 3.25% and the 50-Day Moving Average is 7.1%.
Catalent (NYSE:CTLT): stock turned positive on Friday. Though the stock opened at $23.2, the bulls momentum made the stock top out at $23.56 level for the day. The stock recorded a low of $23.07 and closed the trading day at $23.43, in the green by 1.74%. The total traded volume for the day was 885,457. The stock had closed at $23.03 in the previous days trading.
In an insider trading activity, Walsh Matthew M, officer (See Remarks) of Catalent, Inc., unloaded 21,197 shares at an average price of $28.85 on May 27, 2016. The total amount of the transaction was worth $611,533, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.